{"as_of":"2026-08-16T18:42:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:6530aeb37184e7ba8b0db19320e69b8f8cd3974cd5b018f4c078cda0c4b66381","coverage":[{"denominator":51,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":51,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-14T12:34:29.224850Z","state":"measured"},{"denominator":51,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":51,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-16T06:30:59.297886+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/1908.07112/citation-record","integrity":"/paper/1908.07112/integrity","json":"/paper/1908.07112/citation-record.json","paper":"/paper/1908.07112"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.191942Z","title":"Nonparametric estimation from incomplete observations","venue":null,"work_id":"193afa17-0d81-4c04-80dd-cf6bf51a3f4e","year":1958},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":1,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:28.975601Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ec4b0038599c620b8c2f3c2cb673c24ce787544f92785a7eb9d97a97e1626e20","observation_id":"8108a581-ae81-41b5-baba-8f1cac163010","resolution":{"observed_at":"2026-08-14T12:34:30.196939Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.176149Z","title":"Asymptotically efficient rank invariant test procedures","venue":null,"work_id":"a5333fce-f6e6-4bea-8d4f-eb2571b769cf","year":1972},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":2,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:28.981070Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:3a777414c410f8f097e39d1079955fded11b35ebf90f0a9fe0a617427e6d743e","observation_id":"86906ec5-d65c-4e57-baf4-b2d32a34d61b","resolution":{"observed_at":"2026-08-14T12:34:30.181055Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.161017Z","title":"Regression models and life-tables","venue":null,"work_id":"fe9ab32e-84da-4b54-8f84-340dc9748c56","year":1972},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":3,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:28.986007Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:f65528594fec9545135d75b9b4b8c4d0b7ce1c91dd892682340e8d599ca72944","observation_id":"6e5398b2-a499-438b-9b80-10f4293135c2","resolution":{"observed_at":"2026-08-14T12:34:30.165968Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.145422Z","title":"Statistical issues and challenges in immuno-oncology","venue":null,"work_id":"69303d3f-894d-46ed-a6c5-f3c333be16db","year":2013},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":4,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:28.990774Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ead5d542afa018f872c546c83a798361ee70a46a0c181ef953d35632da06cef8","observation_id":"366d00f5-12d8-4ffe-ab4d-ffb3f1f25243","resolution":{"observed_at":"2026-08-14T12:34:30.150661Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.130534Z","title":null,"venue":null,"work_id":"bb50ae76-ec05-4654-be25-0827e37df23a","year":2015},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":5,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:28.996192Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:31d31ed889f839bc1d0f6c88313e969346c146700075b76eced137f1a6f6bb09","observation_id":"59e49fb8-cad1-4d8b-a42e-aa9eb7e6c289","resolution":{"observed_at":"2026-08-14T12:34:30.135333Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.114501Z","title":"Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer","venue":null,"work_id":"c3a52125-3302-44c2-985e-3844a50b93c1","year":2015},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":6,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.001244Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:1a27dd95d979a09d86a3f451f104afb31130b8a7cf297bc6870d62e2cc16bab7","observation_id":"0a16237a-b114-45ae-ac02-a4b2d22c07a7","resolution":{"observed_at":"2026-08-14T12:34:30.120035Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.097578Z","title":"Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer ( KEYNOTE-010 ): a randomised controlled trial","venue":null,"work_id":"713d5537-5012-42e7-8e16-840048de3209","year":2016},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":7,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.006959Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:21ae9b646e6beae2eb893d37a734dd2ebceeebfb286b2c274277b84766fa2e92","observation_id":"aab611ee-9c64-476a-ad1e-b01be58d12ac","resolution":{"observed_at":"2026-08-14T12:34:30.102792Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.080073Z","title":"A class of rank test procedures for censored survival data","venue":null,"work_id":"46e3ccd3-7a11-40d1-a502-49cb72ac1e62","year":1982},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":8,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.011717Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:2ba51323727dfbb3b2acc786ffe26b9240f80f387f0bd19c055b0cf131c4ea0e","observation_id":"38fad69d-9560-4c0c-bf81-d7d33e407abf","resolution":{"observed_at":"2026-08-14T12:34:30.085658Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.062922Z","title":"Cox analysis of survival data with non-proportional hazard functions","venue":null,"work_id":"1c9e75f1-a590-4511-96b7-5e9e80e54025","year":1992},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":9,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.016708Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:f4f28fa0308a2e300fbf3035d7a440407ec268a3dfa373314ebfc33b8592b076","observation_id":"63ccf99d-5cd8-4e37-a2a2-8eab12ccfe57","resolution":{"observed_at":"2026-08-14T12:34:30.068705Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.046262Z","title":"Designing therapeutic cancer vaccine trials with delayed treatment effect","venue":null,"work_id":"884083e5-5d68-4a84-adca-d60f694d3ecb","year":2017},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":10,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.021449Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:7f570d3f8c7999c0a88842aa3a7a04181e2846bb3b27e1f01d16a51e907daae3","observation_id":"21dec4c6-0c46-4167-9b1b-ef569db6bde3","resolution":{"observed_at":"2026-08-14T12:34:30.051651Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:30.027811Z","title":"Designing cancer immunotherapy trials with random treatment time-lag effect","venue":null,"work_id":"9434e40a-c721-4e28-bdcb-5e6fd427c4d0","year":2018},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":11,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.026956Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:237aeafb11ecef605d130f6b8a5f8fcd74aa2306c74f8bc3c4b879d241961243","observation_id":"d992c7e0-50f2-4589-90f2-f1928c141e17","resolution":{"observed_at":"2026-08-14T12:34:30.033972Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.885430Z","title":"Modestly weighted logrank tests","venue":null,"work_id":"c057e65d-4b13-4d8a-8ff2-cdda3962f939","year":2019},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":12,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.031702Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:9bb48d10ba7460d6700d31488286209d0db7e565c3db8a29c77cfaafce00c925","observation_id":"f4fd1f2b-b71f-4b11-86df-8b2fe6214a2f","resolution":{"observed_at":"2026-08-14T12:34:29.890359Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.869519Z","title":"Analyzing survival curves at a fixed point in time","venue":null,"work_id":"a67feef8-4b0d-49d8-8acd-28e8deb74b74","year":2007},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":13,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.037080Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:055d5cc8ad2e94d460ad4a6f6ba1faebbde4a553f9dac2ef6563963d9eac3b0d","observation_id":"d1184a15-4928-42db-8ed2-4e7c795cfa0b","resolution":{"observed_at":"2026-08-14T12:34:29.874692Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.853719Z","title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","venue":null,"work_id":"8e53f4b5-756b-4b99-893d-ee6a9c9d0928","year":2011},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":14,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.042121Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:2159dfa0863ef4d91076540f12d6f6b7912762a756378d8af9c376cf8ad80aed","observation_id":"cacd3e23-4414-4ab6-9006-249c11093e77","resolution":{"observed_at":"2026-08-14T12:34:29.858829Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.837844Z","title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","venue":null,"work_id":"bb6722b5-5103-48c0-aae7-a43247e9886f","year":2014},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":15,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.047176Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:6196264f93d8940c858b45a96d5257a12ad872c33471f00fec4f95ab353557b7","observation_id":"8f788bda-f256-44a9-9a88-126d608ec85d","resolution":{"observed_at":"2026-08-14T12:34:29.842872Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.822334Z","title":"Predicting the restricted mean event time with the subject's baseline covariates in survival analysis","venue":null,"work_id":"6f36ab38-79d9-4c3b-bcfc-63cd603a1304","year":2014},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":16,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.051979Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:1df54ed045be3d004fe34d7677984d688af3500d744981ba9e2fb0f6c02e2a64","observation_id":"6fc519f0-57cb-4541-8793-9039e7fbe724","resolution":{"observed_at":"2026-08-14T12:34:29.827294Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.806783Z","title":"Weighted kaplan-meier statistics: A class of distance tests for censored survival data","venue":null,"work_id":"b4aef800-123d-42bf-b537-790efc486d93","year":1989},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":17,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.057676Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:c3e2271bd62b3eb55ae89ef23f0f848ee9994ecc660084315af9347dd1eb0288","observation_id":"9565b3df-8df9-4814-9c30-a019c62e20e3","resolution":{"observed_at":"2026-08-14T12:34:29.812187Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.789827Z","title":"Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis","venue":null,"work_id":"2ef885d8-d212-4a6e-8653-159c846d71eb","year":2020},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":18,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.063652Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:7bde8fbe56614c7c058ae3ab1a7cc8ecbaa2030f3dc1128226c14759da3e7aa2","observation_id":"c19e0c91-d340-48f4-9648-f139470f7601","resolution":{"observed_at":"2026-08-14T12:34:29.795008Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.774862Z","title":"Long-term survival with non-proportional hazards: results from the Dutch gastric cancer trial","venue":null,"work_id":"afbb8013-68c9-49bf-a0c5-71aa07e8dd35","year":2005},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":19,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.068463Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:181fa71e72a5a7281a9f94165449f207952b5fc0c23cb2c84a078552dd2fc45c","observation_id":"fd0f947b-7e96-43e1-b3a3-113d6104d4db","resolution":{"observed_at":"2026-08-14T12:34:29.779626Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.758535Z","title":"Testing treatment effect in randomized clinical trials with possible nonproportional hazards","venue":null,"work_id":"8e60527b-9b12-4884-9921-4a3e4e679866","year":2017},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":20,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.073413Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:8949298ceb6c6915775ded1d3e994a86d80f4a1cf7f452462bed70f298fbdd95","observation_id":"e710538f-8206-4e3b-983c-7b3fe3d6f568","resolution":{"observed_at":"2026-08-14T12:34:29.763891Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.742940Z","title":"On the versatility of the combination of the weighted log-rank statistics","venue":null,"work_id":"78e77de9-704a-433e-8234-d83916115ce6","year":2007},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":21,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.078887Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:b5627438195f50debd55beb02d5fc5629e2cc77537455a0530dcc3fb8caa06f5","observation_id":"b81c3c66-99da-4de4-9a1f-44f1fe714879","resolution":{"observed_at":"2026-08-14T12:34:29.747800Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.727145Z","title":"Some versatile tests based on the simultaneous use of weighted logrank and weighted kaplan-meier statistics","venue":null,"work_id":"5e3431fe-11bc-4b68-84f1-89c940e68fa1","year":2001},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":22,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.083971Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:603835e0a43423d4efea265f11d9c1403ad7809e8c53f3ebfb3419c3e7c4d043","observation_id":"3808b5c6-b0ef-4212-b824-beefbe9cf9ce","resolution":{"observed_at":"2026-08-14T12:34:29.732281Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.711001Z","title":"A two-sample censored-data rank test for acceleration","venue":null,"work_id":"daa62f06-912a-4bfd-a9d4-e6a6b6499f36","year":1984},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":23,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.089063Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ee6c18f611234a09cf468e3a89dfd91440162d39ed417bd9818423541548465f","observation_id":"d0a29af6-6e45-40e0-9274-f003558aff40","resolution":{"observed_at":"2026-08-14T12:34:29.715967Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.695237Z","title":"Some versatile tests based on the simultaneous use of weighted log-rank statistics","venue":null,"work_id":"28a8e71d-7ca1-42d7-80a1-aaed02d67690","year":1996},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":24,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.094077Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:73137848c20b35ed2b61aa18bc3e89d1f670d1e1186190308c27b87780fc91fe","observation_id":"c901aefe-a061-4a4f-9c54-4f5726aad484","resolution":{"observed_at":"2026-08-14T12:34:29.700197Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.679942Z","title":"Comparing treatments in the presence of crossing survival curves: An application to bone marrow transplantation","venue":null,"work_id":"c9b81794-ae4f-4566-9fbc-f7c80e4340b0","year":2008},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":25,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.099098Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:74cd5b4bfe98ecacd58bcc949dc451b4a41988b4b715b9445455b64b41b2c13a","observation_id":"45d2bdad-941b-4307-b4ed-ddcc53a86dbb","resolution":{"observed_at":"2026-08-14T12:34:29.685075Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.664458Z","title":"Improved logrank-type tests for survival data using adaptive weights","venue":null,"work_id":"a13dd2d4-3359-46e7-9b0f-625a8ce08f9e","year":2010},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":26,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.103968Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:4696172fdc83ab667a75ed0bf694a3fb510d10bcc9b7247fdbe703134d23f578","observation_id":"3deb350f-1448-491b-bd14-7bf446efb333","resolution":{"observed_at":"2026-08-14T12:34:29.669503Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.648805Z","title":"Versatile tests for comparing survival curves based on weighted log-rank statistics","venue":null,"work_id":"fd0c7e78-ff44-47ab-95cb-10a5da59828c","year":2016},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":27,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.108663Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:c7d777187be9640929eda40e1725b15204053f4727e85e8fb6484cdac9905409","observation_id":"7c79a9be-d451-4650-8253-335cae778e2c","resolution":{"observed_at":"2026-08-14T12:34:29.654138Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.633262Z","title":"Linear regression with censored data","venue":null,"work_id":"a6f82b39-972a-4d95-8885-938417bf0fff","year":1979},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":28,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.113530Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:abdd5b18ddec94e452326d46d8fcabec093be6b0cbed826e7f85af2c3b0f59bc","observation_id":"b1b1965f-79b4-4855-8c51-7e7ea86e1810","resolution":{"observed_at":"2026-08-14T12:34:29.638567Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.618540Z","title":"Linear rank tests with right censored data","venue":null,"work_id":"8b890072-9f42-43a9-9656-c33cf754344f","year":1978},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":29,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.118543Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ff7d3266df449e4ee2a6cf14baf9e39b2d4b5a62713293a0dd3785d1af264529","observation_id":"c6ca4f57-25f9-40d6-915a-01b2865fcad8","resolution":{"observed_at":"2026-08-14T12:34:29.623270Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.603601Z","title":"Innovative estimation of survival using log-normal survival modelling on accent database","venue":null,"work_id":"1c3488d8-c93d-4fd3-a6a8-0eddaadd2f84","year":2013},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":30,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.123292Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:cdcfe2d894ff15500c90cc43c31b2e459401e303ee37440414d5728a7fb1c5a4","observation_id":"b2dd6b34-5667-4701-b4c1-1df148f44ce0","resolution":{"observed_at":"2026-08-14T12:34:29.608384Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.588489Z","title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","venue":null,"work_id":"731a4c00-0fc3-485b-b019-5007d002812d","year":2010},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":31,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.128538Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:82f7a6942b3bcdc36ac8bafe32c409ea5f29e709617bfabaa06a535132ecaa1b","observation_id":"8ef78264-cbab-4793-84d5-f61ec43fe8a8","resolution":{"observed_at":"2026-08-14T12:34:29.592997Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.572912Z","title":null,"venue":null,"work_id":"2b30de25-06a8-4c30-876b-7b1909ff119c","year":2016},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":32,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.133062Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:5113e771a898829ef5f29f1d938e885de73c35947fb2c841489f56a6c21fafae","observation_id":"902909d2-c574-4088-8a31-83ab92c9b3e3","resolution":{"observed_at":"2026-08-14T12:34:29.578279Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.556194Z","title":null,"venue":null,"work_id":"9869f098-bf02-4455-9e06-c0aa697983d2","year":1998},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":33,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.138025Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:d317c52a5d46e2ab0a76519250561b04371e65200de532f50eeade562e7af28e","observation_id":"379e33fc-adb8-41b7-979d-411111047e53","resolution":{"observed_at":"2026-08-14T12:34:29.562028Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.540718Z","title":"Journal of Computational and Graphical Statistics 1992; 1(2): 141--149","venue":null,"work_id":"59b4f772-fd90-4138-87ce-c8d9ad5f0841","year":1992},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":34,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.142714Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:fd572d386f325b968729406b0e1512bc393a3034340a1a3603240ebe273e2d12","observation_id":"1cd8d44b-e496-4c97-acfc-270e29b01e48","resolution":{"observed_at":"2026-08-14T12:34:29.545658Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.524930Z","title":"Methods for accommodating nonproportional hazards in clinical trials: Ready for the primary analysis? Journal of Clinical Oncology 2019; 37(35): 3455--3459","venue":null,"work_id":"acb9cbcc-bf76-4f76-ba00-82ad6eb2a382","year":2019},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":35,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.147329Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:0896388bf3328ac331b958cb5b9f43897a82bd698b5e5b8e375079868939fc05","observation_id":"fe7cdcbd-b195-4a0c-b365-695e892a54fa","resolution":{"observed_at":"2026-08-14T12:34:29.530003Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.509524Z","title":"Monitoring for lack of benefit: A critical component of a randomized clinical trial","venue":null,"work_id":"cd88a79c-f500-4845-860f-7ed6af924399","year":2009},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":36,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.151956Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:52296fc09c681c2bd20a8773de61881f9cc4d07ec007910b0913572bdea1104d","observation_id":"2d227bd6-eca2-4ecb-a006-ab85d355a25b","resolution":{"observed_at":"2026-08-14T12:34:29.514262Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.493818Z","title":"The consequences of proportional hazards based model selection","venue":null,"work_id":"1524c959-731d-4514-915a-5b7b3704a080","year":2014},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":37,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.156876Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:171b78870158e51dba101d8af070a7b8207fa74728033fefb327ecbbd59a50e9","observation_id":"14e2c214-b338-4c20-a921-5ccd8651049a","resolution":{"observed_at":"2026-08-14T12:34:29.498658Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.479407Z","title":"Proportional hazards tests and diagnostics based on weighted residuals","venue":null,"work_id":"a0fef931-dd1e-47cc-a29e-c2b3472ba6d4","year":1994},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":38,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.161342Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:56fbbfcde3f4435f5a111f128270fd25d1685febdef41d4adcbb79a6c8c0e141","observation_id":"57001ebd-d1e5-4dcd-8ccf-7b04518badff","resolution":{"observed_at":"2026-08-14T12:34:29.483961Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.463855Z","title":"The estimation of average hazard ratios by weighted cox regression","venue":null,"work_id":"92a9e35e-9127-415c-8263-67e829165449","year":2009},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":39,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.166199Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:a34d07480620ae0c309ffb3e34bce6fc3eef0621a5255c36e300c2200b83dd0e","observation_id":"20864a17-01ac-43c3-b010-2ba8d7a6890b","resolution":{"observed_at":"2026-08-14T12:34:29.468832Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.447051Z","title":"Estimating average regression effect under non-proportional hazards","venue":null,"work_id":"143c179b-b2bc-4646-87e1-860243e7c89a","year":2000},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":40,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.171002Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:fba4556c8e2a953927c970a7394328efb6695b16a218627e7ba945aa7efe7f1d","observation_id":"1d0d7606-21d6-415a-8972-63159d902198","resolution":{"observed_at":"2026-08-14T12:34:29.452787Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.428797Z","title":null,"venue":null,"work_id":"34b42cdb-c8f6-4268-8433-c8706c7253a5","year":2018},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":41,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.175782Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:2bae79ecb9a28d1f319e0db65dc35e9c5b5a89bc1e293fd943ce91a29c7cf40b","observation_id":"a3e59004-fd59-4ce3-931c-0c4193aac1ba","resolution":{"observed_at":"2026-08-14T12:34:29.435453Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.412640Z","title":"Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-meier survival curves","venue":null,"work_id":"9baa3fbf-105e-4bd1-bc2d-c4cced831b5c","year":2012},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":42,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.180844Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ae7697035d9b1d0a70c47ddffcc3f75211acf62c34220a256c1edf0fe3f667dc","observation_id":"c5421182-533d-490f-8f3e-10dd2fe2488d","resolution":{"observed_at":"2026-08-14T12:34:29.417834Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.396290Z","title":null,"venue":null,"work_id":"13a1e34f-312b-47ad-853e-5c23e2f9b5b8","year":2019},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":43,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.185975Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:5e8974b8d2715190c4110c1c78e9aae2e7c492e1c3225ef0dfa252b1064f8258","observation_id":"7544c108-8bfb-49df-9a1e-23f6ca7529f0","resolution":{"observed_at":"2026-08-14T12:34:29.401419Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.379571Z","title":null,"venue":null,"work_id":"9160e810-8587-476c-8bf4-551bd450a7c3","year":2007},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":44,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.190772Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:f277716de978798d67a874b16d2dd858a75a00d5c7f3f85a492c1acee1468264","observation_id":"3aaa76e4-64ea-41b8-9530-2d42757715d7","resolution":{"observed_at":"2026-08-14T12:34:29.384304Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.362583Z","title":"Group sequential tests for long-term survival comparisons","venue":null,"work_id":"6b05d133-d020-434e-a93d-35e997c2a06d","year":2015},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":45,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.196135Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:ea0426ad9cd2386c793daa5d10242412d11b3f849c784844266b8c2070e862dc","observation_id":"f7749ae5-5540-4d95-8293-a16f372c1c63","resolution":{"observed_at":"2026-08-14T12:34:29.368438Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.345224Z","title":"Sample size determination for the weighted log-rank test with the fleming–harrington class of weights in cancer vaccine studies","venue":null,"work_id":"5b2e8899-1d74-4d8e-a4e3-9ff55b03315f","year":2014},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":46,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.200883Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:bdb1646675db0c75b4df447d5b99a9c51dd060127afb3e479e10cef4f3b83134","observation_id":"7e7cc105-e155-47ba-ad7c-b01d921d2cf0","resolution":{"observed_at":"2026-08-14T12:34:29.350578Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.327016Z","title":"Group sequential monitoring based on the weighted log-rank test statistic with the fleming–harrington class of weights in cancer vaccine studies","venue":null,"work_id":"e0130fcf-bf33-4d0f-84e7-1ac43560a0b9","year":2016},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":47,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.205668Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:839ad50d85111dc31a28c4305dbfc5d413b38d057617c1af3fc18412798045af","observation_id":"45d39089-6b05-420e-9716-6b8f88db46d8","resolution":{"observed_at":"2026-08-14T12:34:29.332104Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.310607Z","title":"Repeated significance testing for a general class of statistics used in censored survival analysis","venue":null,"work_id":"0c8515bf-6fd9-4c44-8327-d26ecb5a7d94","year":1982},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":48,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.210257Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:a7da2fdad8b0f2c568fb202c51052cad5a8c518792219e2d8099e18dbed0894a","observation_id":"19ecf86f-3c92-4261-8544-a764ca5aa17c","resolution":{"observed_at":"2026-08-14T12:34:29.315966Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.293708Z","title":"Interim analysis: The alpha spending function approach","venue":null,"work_id":"1650451f-a0cd-4f90-82e1-dbaab0f9b11f","year":1994},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":49,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.215039Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:f0125b6036e8f932dd70b30257761c58212b0040200b4f975dd2a8ab5d132b43","observation_id":"a5630240-8882-4190-998a-884cd892c4fc","resolution":{"observed_at":"2026-08-14T12:34:29.298975Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.277859Z","title":null,"venue":null,"work_id":"5336fed3-cb9a-43ed-8e70-c767e9398e53","year":null},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":50,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.219900Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:5146410c4236bd8146b3ae8a4f5a08a57f9ecaca31c7d7329c75afa19d6d6f9b","observation_id":"3057f472-a5fa-49c9-b8c2-bfd384cc6085","resolution":{"observed_at":"2026-08-14T12:34:29.282760Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-14T12:34:29.258931Z","title":"Modeling Survival Data: Extending the C ox Model","venue":null,"work_id":"255c7276-7fb7-448c-9e78-19e0144f81ae","year":2000},"citing_paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group","version":4},"reference_index":51,"source":"arxiv_source","source_observed_at":"2026-08-14T12:34:29.224850Z"},"links":{"citing_paper":"/paper/1908.07112"},"observation_digest":"sha256:2b8a5ebf2381b1422257f5e6c2d9079450a9f0a0cbcb22c6b45ceeaced99a462","observation_id":"a004391f-da67-4ae4-b3de-b0d3c099b1cd","resolution":{"observed_at":"2026-08-14T12:34:29.266264Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-16T06:30:59.297886+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"state":"measured"}}],"paper":{"arxiv_id":"1908.07112","last_updated":"2021-01-12T06:02:12Z","latest_version":4,"primary_category":"stat.AP","snapshot_observed_at":"2026-08-14T12:23:45.484235Z","submitted_at":"2019-08-20T00:01:29Z","title":"Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group"},"reference_resolution":{"displayed":51,"state_counts":{"malformed_identifier":0,"metadata_mismatch":0,"parse_uncertain":0,"unresolved":7,"verified_exact":0,"verified_fuzzy":44},"total_outbound_references":51},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-16T06:30:59.297886+00:00","source":"crossref"},{"observed_at":"2026-08-16T06:30:54.164669+00:00","source":"retraction_watch"}],"thesis":"As of 16 August 2026, this Paper Citation Record lists 51 of 51 outbound references and 0 inbound Pith citation observations for arXiv:1908.07112."}